Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Approaches at the American Urological Association Meeting in Washington, D.C.
PALO ALTO, Calif., May 11, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) will showcase the company's full spectrum of prostate cancer treatment technologies at the upcoming American Urological Association (AUA) Meeting in Washington, D.C. During the meeting, Varian will sponsor a series of presentations covering emerging treatments and multi-disciplinary approaches to prostate cancer care.
Within the company's exhibit, Varian will showcase its latest solutions for high- and low-dose-rate brachytherapy, intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy (SBRT), an emerging and promising new approach that involves delivering higher doses to the prostate over a shorter time period than would be the case with conventional radiotherapy. "Varian offers state-of-the-art technology for all of the commonly-used radiotherapy approaches to treating prostate cancer," said Calvin Huntzinger, MS, senior director, Varian Surgical Sciences.
Presentations Explore New Options in Prostate Cancer Care
On Sunday, May 15, and again on Monday, May 16, a select group of eminent surgeons, urologists, radiation oncologists, and researchers will deliver 20-minute mini-lectures on major advances in their fields of specialization, with a particular focus on how multidisciplinary collaboration can benefit patients. The lectures will take place in the Varian booth (#3043). The presentations will include:
- Constantine A. Mantz, MD, chief medical officer at 21st Century
Oncology in Fort Myers, Florida, on stereotactic body radiotherapy
(SBRT) as an emerging treatment for prostate cancer. Dr.
Mantz has been conducting Phase II SBRT trials using Varian
technology to deliver five treatments over a two-week period, with
promising preliminary results that appear to support the use of